RESUMO
The main goal of this online survey was to investigate the attitudes of Brazilians towards "cell-based meat", which has become the subject of great scientific and media enthusiasm. The answers of 4471 respondents concluded that 46.6% of them thought "cell-based meat" was promising and acceptable. More than 66% would be willing to try this novel product compared to 23% who expressed reluctance to do so. Nearly 40% of the total respondents did not want to eat "cell-based meat" regularly at all, whereas 29%, 43.2%, and 39.9% were willing to eat it regularly in restaurants, at home, and/or in ready-made meals, respectively. However, the majority of respondents (71%) were keen to pay much less for "cell-based meat" than conventionally produced meat (or even nothing at all), compared to 24.3% who were willing to pay the same price as conventional meat, whereas only 4.8% were willing to pay more. Approximately 51% of them considered that "cell-based meat" should not be called "meat" for marketing purposes. Job, monthly income, age, and gender were major factors impacting consumer acceptance. Meat professionals and consumers with higher incomes were less willing to eat "cell-based meat" regularly. Women (especially younger women) were the most concerned about the ethical and environmental issues related to meat production and were the most convinced that reducing meat consumption could be a good solution to the meat industry's problems. Respondents who did not accept "cell-based meat" and did not eat meat substitutes had a negative attitude to this novel food (they considered it absurd and/or disgusting) and did not believe that "cell-based meat" should be called "meat" for marketing purposes. In contrast, the people who thought that "cell-based meat" could be called "meat" perceived it in a rather positive way. These results are important for consumers of meat and meat substitutes and for companies aiming to enter the potential future Brazilian market of "cell-based meat".
RESUMO
In the Yucatán Peninsula of Mexico, the main vector of Chagas disease is Triatoma dimidiata. Field studies suggest that natural transmission occurs through transient and seasonal invasion of houses by sylvatic/peridomestic triatomines, rather than through persistent domiciliated bug populations. We investigated the genetic structure of T. dimidiata populations, using morphometry and microsatellite markers, to assess dispersal of individuals in this triatomine species and to understand the dynamics of domestic infestation. We observed low phenotypic and genetic differentiation among populations from different villages, with an FST of only 0.0553, which suggested a weak but significant population structure at this level. Similarly low but significant differences were observed among populations from the same village but different biotopes (sylvatic, peridomestic, and domestic), with FST values ranging from 0.0096 to 0.0455. These data suggested elevated dispersal of bugs between biotopes (Nm = 5-25), which was confirmed by likelihood and Bayesian assignment tests. A proportion of bugs collected within domiciles were significantly assigned to peridomestic and sylvatic areas. This study showed that T. dimidiata has important dispersal capabilities that can explain the seasonal pattern of domicile infestation by peridomestic and sylvatic bugs. Therefore, dispersal should be taken into account in the design of effective vector control strategies.
Assuntos
Insetos Vetores/fisiologia , Repetições de Microssatélites/genética , Triatoma/fisiologia , Animais , Doença de Chagas/transmissão , Demografia , Feminino , Frequência do Gene , Genótipo , Insetos Vetores/anatomia & histologia , Insetos Vetores/genética , Masculino , México , Triatoma/anatomia & histologia , Triatoma/genéticaRESUMO
BACKGROUND: Sensor-augmented pump therapy (SAP) provides a useful adjunct relative to continuous subcutaneous insulin infusion (CSII) alone. It can provide early warning of the onset of hyperglycemia and hypoglycemia and has the functionality to suspend insulin delivery if sensor glucose levels fall below a predefined threshold. The aim was to assess the cost-effectiveness of SAP with low glucose suspend (LGS) versus CSII alone in type 1 diabetes. MATERIALS AND METHODS: Cost-effectiveness analysis was performed using the CORE Diabetes Model, using published clinical input data. The analysis was performed in two cohorts: one with uncontrolled glycated hemoglobin at baseline and one at elevated risk for hypoglycemic events. The analysis was conducted from a healthcare payer perspective over a lifetime time horizon; future costs and clinical outcomes were discounted at 4% per annum. RESULTS: In patients with uncontrolled glycated hemoglobin at baseline, SAP + LGS resulted in improved discounted quality-adjusted life expectancy (QALE) versus CSII (10.55 quality-adjusted life-years [QALYs] vs. 9.36 QALYs) but higher mean lifetime direct costs (84,972 vs. 49,171) resulting in an incremental cost-effectiveness ratio (ICER) of 30,163 per QALY gained. In patients at elevated risk for hypoglycemia, the ICER was 22,005 per QALY gained for SAP + LGS versus CSII as lifetime costs were higher (88,680 vs. 57,097), but QALE was also higher (18.46 QALYs vs. 18.30 QALYs). CONCLUSIONS: In France, projected improvements in outcomes with SAP + LGS versus CSII translated into an ICER generally considered as good value for money, particularly in patients who experience frequent and/or problematic hypoglycemic events.